Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201078 | 0.98 | SLC6A3 (0.38) | SLC6A3ABCB1TDP2SMN1; SMN2WDR5 | |
| SCHEMBL2195538 | 0.96 | ABCB1 (0.38) | SLC6A3ABCB1TDP2SMN1; SMN2WDR5 | |
| SCHEMBL2199935 | 0.85 | TDP2 (0.39) | ABCB1TDP2MAPK1MAP3K5 | |
| SCHEMBL2198291 | 0.83 | TDP2 (0.39) | ABCB1TDP2MAPK1MAP3K5 | |
| SCHEMBL2195168 | 0.82 | DGAT1 (0.36) | MAPK1MAP3K5 | |
| SCHEMBL2195751 | 0.81 | TDP2 (0.40) | ABCB1TDP2MAPK1MAP3K5 | |
| SCHEMBL2199646 | 0.79 | DGAT1 (0.36) | TDP2MAPK1 | |
| SCHEMBL13719112 | 0.78 | PTPN1 (0.44) | SMN1; SMN2MAPK1 | |
| SCHEMBL13718913 | 0.77 | ABCB1 (0.43) | ABCB1 | |
| SCHEMBL2179489 | 0.77 | CYP2C19 (0.40) | SLC6A3ABCB1TDP2SMN1; SMN2WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | SLC6A3 602/4885ABCB1 1179/4885TDP2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.